Artal Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Artal Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-150,000	Closed	-$1.91M	–	138
2017 Q4	$1.91M	Sell	150,000 -50,000	-25%	-$735K	0.03%	96
2017 Q3	$3.12M	Sell	200,000 -50,000	-20%	-$707K	0.05%	81
2017 Q2	$3.51M	Sell	250,000 -50,000	-17%	-$1.07M	0.06%	77
2017 Q1	$6.6M	Buy	+300,000	New	+$6.36M	0.15%	52

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's JNCE Position: Q1 2018 in Review

Artal Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2018, closing a stake of 150,000 shares — an estimated $1.91M sold.

Artal Group first reported a position in JNCE in Q1 2017 and held it in 4 quarters. The position peaked at $6.6M in Q1 2017. 94 funds tracked by Wall St. Rank hold JNCE as of Q1 2018.

Artal Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Artal Group sold 150,000 Jounce Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $1.91M.
Artal Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Artal Group's Jounce Therapeutics, Inc. Common Stock position peaked at $6.6M in Q1 2017.
94 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.